Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
153.66B
Market cap153.66B
Price-Earnings ratio
23.56
Price-Earnings ratio23.56
Dividend yield
3.22%
Dividend yield3.22%
Average volume
1.78M
Average volume1.78M
High today
$287.23
High today$287.23
Low today
$284.87
Low today$284.87
Open price
$287.23
Open price$287.23
Volume
1.89M
Volume1.89M
52 Week high
$339.17
52 Week high$339.17
52 Week low
$253.30
52 Week low$253.30

AMGN News

Seeking Alpha 13h
Veeva partners with Amgen to speed up clinical trials

Healthcare Veeva partners with Amgen to speed up clinical trials Aug. 28, 2025 9:30 AM ET Veeva Systems Inc. (VEEV) Stock By: Soumendra Mukherjee, SA News Edito...

Veeva partners with Amgen to speed up clinical trials
TipRanks 20h
Amgen’s Repatha: Balancing Growth Potential with Long-Term Risks

Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating on August 26. Elevate Your Investing Strategy: T...

Simply Wall St 3d
Royalty Pharma Acquires US$885 Million Royalty Interest In Amgen's Imdelltra

recently acquired a royalty interest in Amgen's Imdelltra, a move that may have added confidence to investors, contributing to the company's 11% share price inc...

Royalty Pharma Acquires US$885 Million Royalty Interest In Amgen's Imdelltra

Analyst ratings

48%

of 33 ratings
Buy
42.4%
Hold
48.5%
Sell
9.1%

More AMGN News

TipRanks 4d
Royalty Pharma Stock Rises as it Seals $950M Cancer Royalties Deal with Amgen

Shares in Royalty Pharma (RPRX) were higher today after snapping up a royalty interest in pharmaceutical group Amgen’s (AMGN) new cancer drug. Elevate Your Inv...

TipRanks 4d
Amgen price target raised to $342 from $328 at Piper Sandler

Piper Sandler raised the firm’s price target on Amgen (AMGN) to $342 from $328 and keeps an Overweight rating on the shares following quarterly results. With co...

TipRanks 4d
Royalty Pharma confirms acquisition of royalty interest in Amgen’s Imdelltra

Royalty Pharma (RPRX) announced that it has acquired a royalty interest in Amgen’s (AMGN) Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager,...

TipRanks 6d
Amgen’s New Clinical Study: A Potential Game Changer in Lung Cancer Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

TipRanks 6d
Amgen’s Promising Asthma Treatment: Rocatinlimab Study Update

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 6d
Amgen’s AMG 193 Study: A New Hope for Advanced Thoracic Tumors

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 6d
Amgen’s Dazodalibep Study: A Promising Step for Sjögren’s Syndrome Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.